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Introduction {#sec005}
============

Standardization of anti-rheumatic treatment improves prognosis in patients with rheumatoid arthritis (RA). Tumor necrosis factor (TNF) antagonists are highly effective but associated with increased risk of tuberculosis (TB), mostly due to reactivation of a latent infection \[[@pone.0233159.ref001], [@pone.0233159.ref002]\]. Therefore, patients must be screened for latent TB infection (LTBI) before initiating anti-TNF agents. National recommendations for LTBI screening based on patient medical history, clinical examination, tuberculin skin testing (TST), and chest radiographs have been effective in reducing TB incidence \[[@pone.0233159.ref003]\]. However, the incidence of TB remains higher in patients receiving anti-TNF therapy compared with the general population \[[@pone.0233159.ref004], [@pone.0233159.ref005]\]. Furthermore, TST has well-known limitations: poor specificity due to cross-reactivity with environmental mycobacteria or bacillus Calmette--Guérin (BCG) vaccination \[[@pone.0233159.ref006]\] and poor sensitivity in immunocompromised patients \[[@pone.0233159.ref007], [@pone.0233159.ref008]\].

Interferon (IFN)-γ release assays (IGRAs) have been established as a screening test for LTBI. IGRAs are *in vitro* tests that rely on the rapid production of IFN-γ by CD4-positive effector memory or central memory T cells after stimulation with TB-specific antigens. In the general population, IGRAs are more effective than TST for diagnosing active TB infection or LTBI \[[@pone.0233159.ref009]\]. In 2010, the Centers for Disease Control and Prevention updated the guidelines for using IGRAs to detect TB infection \[[@pone.0233159.ref010]\]; IGRAs are recommended, because prior BCG vaccination does not lead to false-positive results. In clinical rheumatology, IGRAs are useful for diagnosing LTBI before the initiation of biologic therapy, such as anti-TNF agents \[[@pone.0233159.ref011]\]. Two different IGRAs for diagnosing TB infection---QuantiFERON-*TB* (QFT) and T-SPOT.*TB*---are currently available. Because whole blood is used in the QFT assay, the results may be affected by immunosuppressive therapies for RA \[[@pone.0233159.ref012]\]. On the other hand, the effect of immunosuppressive therapies may be less in T-SPOT.TB assay than in QFT because it is performed using isolated peripheral blood mononuclear cells (PBMCs); any immunosuppressive agents present are washed out \[[@pone.0233159.ref012]\]. Moreover, the T-SPOT.*TB* protocol is considerably easier to perform than the QFT protocol. The incidence of invalid results for the T-SPOT.*TB* assay is reportedly as low as 0.6% \[[@pone.0233159.ref013]\]. Therefore, this assay may be a useful tool for diagnosing LTBI in RA patients receiving immunosuppressive therapy.

Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 is endemic in Japan, where there are approximately 1 million HTLV-1 carriers \[[@pone.0233159.ref014]\]. CD4-positive T cells are the main target of the HTLV-1 virus. Some reports have found that the TST reaction in HTLV-1-positive individuals is attentuated compared with that in HTLV-1-negative individuals \[[@pone.0233159.ref015], [@pone.0233159.ref016]\]. These reports also suggest that HTLV-1 affects the adaptive immune response via HTLV-1-infected CD4-positive T cells. In addition, other reports have demonstrated that PBMCs isolated from HTLV-1-infected individuals automonously produce IFN-γ in cell culture conditions \[[@pone.0233159.ref017], [@pone.0233159.ref018]\]. However, the effect of HTLV-1 infection on TB IGRA results in RA patients remains unclear. Therefore, the present study aimed to evaluate the use of the T-SPOT.*TB* assay in HTLV-1-positive RA patients. In addition, the association between IFN-γ-producing T cells and HTLV-1 proviral loads in HTLV-1-positive RA patients was examined. The present study demonstrated that HTLV-1 infection may invalidate T-SPOT.*TB* assay results in RA patients. Furthermore, HTLV-1-positive RA patients who have the high HTLV-1 PVL values tended to be showing invalid results for T-PSOT.*TB* assay.

Materials and methods {#sec006}
=====================

Study design and participants {#sec007}
-----------------------------

The HTLV-1 RA Miyazaki Cohort Study was conducted from August 2012 to July 2019 at the Miyazaki University Hospital and Zenjinkai Shimin-no-Mori Hospital in the Miyazaki Prefecture, Japan \[[@pone.0233159.ref019]\]. The aim of this cohort study was to clarify the impact of HTLV-1 infection on the clinical features of RA patients and to investigate whether immunosuppressive therapies alter the risk factors associated with the development of ATL in HTLV-1-positive RA patients. A total of 858 RA patients were enrolled in this cohort. All participants were diagnosed with RA on the basis of the 1987 diagnostic criteria of the American College of Rheumatology (ACR) and screened for HTLV-1 infection \[[@pone.0233159.ref020]\]. Accordingly, 54 HTLV-1-positive RA patients were enrolled in this cohort. All RA patients were treated with anti-rheumatic drugs, such as methotrexate (MTX) and biologic agents, in accordance with RA treatment guidelines \[[@pone.0233159.ref021]\]. Written informed consent was obtained from all participants. These patients were expected to periodically visit the Miyazaki University and Zenjinkai Shimin-no-Mori Hospitals for clinical assessment and sample collection \[[@pone.0233159.ref019]\].

The participants of the present study were selected from this cohort. The inclusion criteria of this study as follows: HTLV-1-positive RA patients who underwent T-SPOT.*TB* assay (Oxford Immunotec, Oxford, UK) in this cohort from April 2012 to July 2019. The reasons for performing T-SPOT.*TB* assay was to detect LTBI before the initiation of treatment with biologic agents. In addition, the assay was performed when chest radiographs during anti-rheumatic treatment revealed findings suspicious for LTBI, such as pleural wall thickening, bronchial ectasia, and pleural effusion. According to this inclusion criteria, 29 of 54 HTLV-1-positive RA patients were enrolled into this study ([Fig 1](#pone.0233159.g001){ref-type="fig"}). Furthermore, 341 HTLV-1-negative RA patients had undergone T-SPOT.*TB* assay in this cohort during same observation period. Accordingly, 3 age- and sex-matched HTLV-1-negative RA patients from 341 HTLV-1-negative RA patients were selected as controls for each HTLV-1-positive RA patient; age was matched to within 5 years ([Fig 1](#pone.0233159.g001){ref-type="fig"}). To avoid sampling biases, the selection of the participants as controls was randomly performed from these 341 HTLV-1-negative RA patients based on sex and age, except for any other clinical information. Overall, 87 HTLV-1-negative RA patients were enrolled as controls in the present study. All clinical information evaluated during LTBI screening such as a previous TB history, TST results, T-SPOT.*TB* assay results, RA disease activity, anti-rheumatic regimen, white blood cell (WBC) count, and lymphocyte count were collected from medical records of these participants. The study protocol was approved by the research ethics committees of the Miyazaki University Hospital (approval no. O-0236) and Zenjinkai Shimin-no-Mori Hospital and followed the Ethical Guidelines for Medical and Health Research Involving Human Subjects.

![The number of participants with RA who underwent T-SPOT.*TB* in HTLV-1 RA Miyazaki cohort.\
A total of 29 HTLV-1-positive RA patients were evaluated for latent *Mycobacterium tuberculosis* infection using the T-SPOT.*TB* assay. Further, 341 HTLV-1-negative RA patients underwent T-SPOT.*TB* assay in this cohort. Accordingly, 3 age- and sex-matched HTLV-1-negative RA patients were selected as controls for each HTLV-1-positive RA patient. Finally, 29 HTLV-1-positive RA and 87 HTLV-1-negative RA patients were enrolled in this study.](pone.0233159.g001){#pone.0233159.g001}

IFN-γ release assay {#sec008}
-------------------

T-SPOT.*TB* assays (Oxford Immunotec, Oxford, UK) were performed by the CRC clinical laboratory company (Fukuoka, Japan), according to manufacturer's instructions \[[@pone.0233159.ref022]\]. Briefly, the assays were considered invalid if the negative control spot count was \>10 or if the positive control spot count was \<20 (low positive control). For valid tests, the result was obtained (positive, negative, or borderline) by subtracting the spot count of the negative control from the highest spot count found between panels A (TB-specific antigen ESAT-6) and B (TB-specific antigen CFP-10). In this assay, when high background staining occurs hindering the discrimination of the spots from the background, the results were considered invalid. Therefore, if negative control spot count was \>10 spots, the T-SPOT.*TB* assay result was considered invalid regardless of the spot count of both panel A and panel B.

Clinical assessment of RA {#sec009}
-------------------------

Clinical information was collected either immediately before or after performing the T-SPOT.*TB* assay. RA disease activity was assessed using the 28-joint Disease Activity Score (DAS28), erythrocyte sedimentation rate (ESR), and the Clinical Disease Activity Index (CDAI) \[[@pone.0233159.ref023]\].

HTLV-1 proviral load {#sec010}
--------------------

HTLV-1 proviral load (PVL) was determined using peripheral blood samples obtained from HTLV-1-positive RA patients during follow-up clinical visits \[[@pone.0233159.ref019]\]. In HTLV-1-positive RA patients, DNA was purified from WBCs using the QIAamp Blood DNA Midi Kit (Qiagen, Hilden, Germany) and concentrated to 0.5 μg/μL via ethanol precipitation. Real-time PCR was performed to measure the HTLV-1 *pX* region and the human albumin gene using the Light Cycler 2.0 thermal cycler (Roche Diagnostics, Mannheim, Germany) \[[@pone.0233159.ref024]\]. HTLV-1 PVL values in PBMCs were measured in duplicate, and the number of copies per 100 WBCs was calculated: a value of 4.0 copies per 100 PBMCs, which is a known risk factor for ATL development, corresponds to approximately 1.6 copies per 100 WBCs \[[@pone.0233159.ref025]\]. The HTLV-1 PVL values have been stored in the Miyazaki HTLV-1 RA Cohort database \[[@pone.0233159.ref019]\]. HTLV-1 PVL values that were measured immediately before or after performing the T-SPOT.*TB* assay were used in the present study, considering that anti-rheumatic treatments do not affect HTLV-1 PVL values in HTLV-1-positive RA patients \[[@pone.0233159.ref019]\].

Statistical analysis {#sec011}
--------------------

Statistical analyses were performed using EZR, R version 3.6.1. For describing patietns chracteristics, median with interquartile range (IQR) and count with proportion were used for continuous and categorical data, respectively. Group comparison between HTLV-1-negative and HTLV-1-positive RA patients was conducted using logistic regression model for age, the number of WBC and lymphocytes, inflammatory biomarker levels, DAS28, and CDAI. The sex ratio; rate of TST negativity; rate of rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) positivity; and rate of corticosteroid, MTX, and biologic agent use between HTLV-1-negative and HTLV-1-positive RA patients were compared using logistic regression model. The HTLV-1 PVL values in HTLV-1-positive RA patients were compared between patients with negative and invalid results in the T-SPOT.*TB* assay using the Mann--Whitney test. Further, the invalid results of T-SPOT.*TB* assay were evaluated for HTLV-1-positive and negative group by odds ratio. P \< 0.05 was considered significant.

Results {#sec012}
=======

Characteristics of HTLV-1-negative and HTLV-1-positive RA patients {#sec013}
------------------------------------------------------------------

[Table 1](#pone.0233159.t001){ref-type="table"} shows the baseline clinical characteristics of the HTLV-1-negative and HTLV-1-positive RA patients enrolled in this study. There was no difference between the groups with respect to median age, sex ratio, seroprevalence of ACPA/RF, WBC and lymphocyte counts, CRP and ESR levels, and DAS28 and CDAI values. According to the European League Against Rheumatism (EULAR) improvement criteria, the median DAS28 for both groups indicated low RA activity. All patients were treated with disease-modifying anti-rheumatic drugs (DMARDs), including MTX and/or biologic agents, according to the ACR/EULAR guidelines \[[@pone.0233159.ref026]\]. The proportion of patients receiving corticosteroids and DMARDs excluding MTX did not differ between HTLV-1-negative and HTLV-1-positive RA patients. The rate of MTX use, median dosage of MTX, and proportion of patients using biologic agents did not differ between the groups. Both previous TB history and TST results were reviewed from medical records of the HTLV-1-positive and HTLV-1-negative RA patients. There wa no TB history in the HTLV-1-positive RA patients. In HTLV-1-negative RA patients, one of the 87 patients had a history of TB infection. Regarding TST results, 46 HTLV-1-negative and 13-HTLV-1-positive RA patients had undergone TST during the observation period. The rate of TST negativity tended to be high in HTLV-1-positive RA patients than in HTLV-1-negative RA patients (77% vs.67%, P = 0.51).

10.1371/journal.pone.0233159.t001

###### Characteristics of HTLV-1-negative and positive patients with rheumatoid arthritis.

![](pone.0233159.t001){#pone.0233159.t001g}

                                                                                HTLV-1-negative   HTLV-1-positive   P value
  ----------------------------------------------------------------------------- ----------------- ----------------- ---------
  Age, years (IQR)                                                              70 (9.5)          70 (9)            0.94
  Female, no. (%)                                                               69 (79)           23 (79)           \-
  Positive for RF, no. (%) [^a^](#t001fn002){ref-type="table-fn"}               66/84 (78.5)      20/28 (71.4)      0.44
  Positive for ACPA, no. (%) [^b^](#t001fn003){ref-type="table-fn"}             63/79 (79.7)      14/20 (70)        0.35
  CRP (mg/dL) (IQR)                                                             0.18 (1.4)        0.19 (1.1)        0.96
  ESR (mm/60 min) (IQR)                                                         28 (34)           23 (33)           0.17
  DAS28 (IQR) [^c^](#t001fn004){ref-type="table-fn"}                            3.11 (2.1)        2.93 (1.7)        0.61
  CDAI (IQR) [^d^](#t001fn005){ref-type="table-fn"}                             5.0 (11)          6.6 (9.6)         0.93
  White blood cell count (/μL) (IQR)                                            5,654 (2,853)     5,821 (3,024)     0.74
  Lymphocyte count (/μL) (IQR)                                                  1,372 (598)       1,648 (1,053)     0.17
  Patients treated with corticosteroids, no. (%)                                28 (32.2)         14 (48)           0.12
  Corticosteroid dosage (mg/day) (IQR) [^e^](#t001fn006){ref-type="table-fn"}   3.0 (3.0)         2.75 (3.0)        0.29
  Patients treated with conventional DMARDs (excluding MTX), no. (%)            8 (9.2)           5 (17.2)          0.99
  Patients treated with MTX, no. (%)                                            48 (55.1)         12 (41.4)         0.20
  MTX dosage (mg/week) (IQR)                                                    8.0 (4.0)         8.0 (4.5)         0.38
  Patients treated with biologic agents, no. (%)                                57 (65.5)         15 (51.7)         0.18
  Monotherapy (without MTX), no. (%)                                            30 /57 (52.6)     9 / 15 (60)       0.61
  Combination with MTX, no (%)                                                  27/ 57 (47.4)     6 / 15 (40)       0.61

Values are expressed as medians with interquartile range (IQR). Percentages (%) are calculated based on total number of patients in each group unless indicated otherwise. CRP, C-reactive protein; ESR, erythrosedimentation rate; DAS28, 28-Joint Disease Activity Score; CDAI, Clinical Disease Activity Index; DMARDs, disease-modifying anti-rheumatic drugs; MTX, methotrexate.

^a^ Data available in 84 and 28 patients of the HTLV-1-negative and HTLV-1-positive RA groups, respectively.

^b^ Data available in 79 and 20 patients of the HTLV-1-negative and HTLV-1-positive RA groups, respectively.

^c^ Data available in 87 and 26 patients of the HTLV-1-negative and HTLV-1-positive RA groups, respectively.

^d^ Data available in 87 and 25 patients of the HTLV-1-negative and HTLV-1-positive RA groups, respectively.

^e^ Prednisolone equivalent

T-SPOT.*TB* assay results in HTLV-1-negative and HTLV-1-positive RA patients {#sec014}
----------------------------------------------------------------------------

[Table 2](#pone.0233159.t002){ref-type="table"} shows the T-SPOT.*TB* assay results in the HTLV-1-negative and HTLV-1-positive RA patients. Overall, 55% of the HTLV-1-positive RA patients showed invalid results compared with none of the HTLV-1-negative RA patients (odds ratio, 108; p \< 0.0001). The cause of invalidity in the HTLV-1-positive RA patients was a spot count of \>10 in the negative controls ([Table 3](#pone.0233159.t003){ref-type="table"}). The median IFN-γ spot count in the negative control panels was 29.5 among the HTLV-1-positive RA patients with invalid results. The median IFN-γ spot count in the positive control panels of the HTLV-1-positive RA patients did not differ between those with invalid test results and those with negative test results (322 vs. 325, p = 0.93). There was no difference in DMARD dosage or RA disease activity between the HTLV-1-positive RA patients with invalid results and those with negative results ([S1 Table](#pone.0233159.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0233159.t002

###### T-SPOT.*TB* assay results in HTLV-1-negative and HTLV-1-positive patients with rheumatoid arthritis.

![](pone.0233159.t002){#pone.0233159.t002g}

                      HTLV-1-negative (n = 87)   HTLV-1-positive (n = 29)
  ------------------- -------------------------- ------------------------------------------------
  Negative, n (%)     81 (93.1)                  12 (41.4)
  Positive, n (%)     4 (4.7)                    0
  Borderline, n (%)   1 (1.1)                    1 (3.5)
  Invalid, n (%)      1 (1.1)                    16 (55.1)[\*](#t002fn002){ref-type="table-fn"}

HTLV-1: human T-cell leukemia virus type 1.

\*: P \< 0.0001 Odds ratio^※^: 108 (95%CI: 13.1, 890).

※: Odds ratio of patients with HTLV-1 positive RA who have an invalid T-SPOT.*TB* test result to patients with negative RA.

10.1371/journal.pone.0233159.t003

###### IFN-γpositive spot counts in the T-SPOT.*TB* assay panels and HTLV-1 proviral load in HTLV-1-positive patients with rheumatoid arthritis.

![](pone.0233159.t003){#pone.0233159.t003g}

              PVL (copies/100 WBCs)   Spot count in T-SPOT.*TB* assay panels   T-SPOT.*TB* assay result                            
  ------ ---- ----------------------- ---------------------------------------- --------------------------------------- ----- ----- ------------
  Case   1    15.12                   [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   18    240   Invalid
  Case   2    4.43                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   16    346   Invalid
  Case   3    3.89                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   65    489   Invalid
  Case   4    3.84                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   18    467   Invalid
  Case   5    2.95                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   13    307   Invalid
  Case   6    2.88                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   86    338   Invalid
  Case   7    2.83                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   66    219   Invalid
  Case   8    2.6                     [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   102   452   Invalid
  Case   9    2.45                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   28    254   Invalid
  Case   10   2.03                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   17    180   Invalid
  Case   11   2.03                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   11    258   Invalid
  Case   12   1.54                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   185   615   Invalid
  Case   13   1.5                     [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   14    299   Invalid
  Case   14   0.89                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   93    365   Invalid
  Case   15   0.46                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   38    303   Invalid
  Case   16   0.19                    [\*](#t003fn002){ref-type="table-fn"}    [\*](#t003fn002){ref-type="table-fn"}   31    431   Invalid
  Case   17   8.48                    0                                        0                                       0     445   Negative
  Case   18   3.64                    0                                        0                                       0     133   Negative
  Case   19   1.42                    1                                        0                                       1     396   Negative
  Case   20   0.49                    1                                        0                                       0     300   Negative
  Case   21   0.37                    0                                        0                                       1     208   Negative
  Case   22   0.33                    0                                        0                                       4     277   Negative
  Case   23   0.2                     0                                        0                                       3     203   Negative
  Case   24   0.19                    1                                        2                                       0     345   Negative
  Case   25   0.1                     0                                        0                                       0     403   Negative
  Case   26   0.1                     0                                        0                                       4     305   Negative
  Case   27   0.04                    0                                        0                                       1     670   Negative
  Case   28   0.02                    0                                        0                                       0     608   Negative
  Case   29   2.61                    7                                        0                                       2     128   Borderline

WBCs, white blood cells; PVL, proviral load; ESAT-6, early secretary antigen target 6; CFP10: culture filtrate protein 10

\*, unevaluation.

HTLV-1 PVL in patients with invalid and valid T-SPOT.*TB* assay results {#sec015}
-----------------------------------------------------------------------

The median HTLV-1 PVL for the 29 HTLV-1-positive RA patients was 1.54 copies per 100 WBCs (IQR, 2.55). The median HTLV-1 PVL value was significantly higher in the 16 patients who showed invalid T-SPOT.*TB* assay results than in the 12 patients who showed conclusive negative results (2.52 vs. 0.33 copies/100 WBCs; p = 0.003) ([Fig 2](#pone.0233159.g002){ref-type="fig"}).

![Human T-cell leukemia virus type 1 (HTLV-1) proviral load (PVL) in HTLV-1-positive RA patients who showed negative (n = 12) or invalid (n = 16) T-SPOT.*TB* assay results.\
The y-axis indicates HTLV-1 PVL in copies per 100 white blood cells (WBCs). Medians with interquartile range are shown.](pone.0233159.g002){#pone.0233159.g002}

Discussion {#sec016}
==========

This is the first report demonstrating that HTLV-1 infection affects T-SPOT.*TB* assay results in RA patients, suggesting that the T-SPOT.*TB* assay may not be a reliable LTBI screening tool in approximately half of HTLV-1-positive RA patients.

In routine practice with regard to the management of rheumatic diseases, LTBI has been evaluated by IGRAs as well as radiologic examinations using chest high resolution computed tomography (HRCT). Additionally, it is important to determine history of previous TB infection before the administration of immunosuppressive therapy. In the present study, based on history of TB infection, T-SPOT.*TB* results, and HRCT findings, 19 HTLV-1-negative and 3 HTLV-1-positive RA patients were treated with isoniazid as a prophylactic regimen of TB reactivation before the initiation of antirheumatic biologic therapy. Although there was no history of previous TB infection in the HTLV-1-positive RA patients, 3 HTLV-1-positive RA patients had suspicious findings of LTBI in chest-HRCT and were administrated isoniazid. Among of them, 2 HTLV-1-positive RA patients showed an invalid T-SPOT.*TB* assay. In 19 HTLV-1-negative RA patients treated with isoniazid, 1 HTLV-1-negative RA patients had a history of TB infection and showed positive result for T-SPOT.*TB* assay. Further, 18 HTLV-1-negative RA patients had suspicious findings of LTBI in chest-HRCT and were administrated isoniazid. The invalid result of T-SPOT.*TB* assay is reportedly as low as 0.6% \[[@pone.0233159.ref013]\]. Therefore, this assay was recommended as a reliable tool to diagnose LTBI in RA patients receiving antirheumatic therapies including biologic agents. However, our result suggested that HTLV-1 infection may invalidate the T-SPOT.*TB* assay in HTLV-1-positive RA patients. In clinical practice, for the management of HTLV-1-positive RA patients, it is necessary to perform T-SPOT.*TB* assay as well as radiologic examinations for LTBI screening. In addition, if invalid result of T-SPOT.*TB* assay was observed in RA patients in HTLV-1 endemic areas, it would be preferable to consider the assessment of HTLV-1 infection.

Some previous reports have suggested that HTLV-1 infection may attenuate the response to purified protein derivative (PPD) of TB. The proportion of HTLV-1 carriers with low response to PPD of TB reportedly ranges from 65% to 70% \[[@pone.0233159.ref015], [@pone.0233159.ref016]\]. In the present study, the rate of TST negativity was 77% in HTLV-1-positive RA patients, which was high compared with those in previous reports \[[@pone.0233159.ref015], [@pone.0233159.ref016]\]. The reaction to PPD reportedly diminishes with advanced age. One of reasons for this tendency was considered that the median patient age in the present study was high compared with that in a previous report (70 vs. 63, respectively) \[[@pone.0233159.ref015], [@pone.0233159.ref016]\]. Moreover, the rate of TST negativity tended to be higher in HTLV-1-positive RA patients than that in HTLV-1-negative RA patients. Several studies have suggested that immunosuppressive treatments may affect the response to PPD. In patients with rheumatic diseases who have been treated with immunosuppressive agents, the efficacy of TST is influenced by low positive and negative predictive values \[[@pone.0233159.ref027], [@pone.0233159.ref028]\]. In the present study, the background of therapeutic regimens was similar between HTLV-1-negative and HTLV-1-positive RA patients. Therefore, it was considered that HTLV-1 infection may attenuate the TST reaction in HTLV-1-positive RA patients.

The cause of invalid results in the HTLV-1-positive patients was a high spot count in the negative controls (\>10 spots) of the assay. A high spot count in the negative controls indicates the presence of autonomous IFN-γ producing cells without specific TB-antigen stimulation. HTLV-1-infected T cells often behave in a similar manner to T helper (Th) 1-like cells, which autonomously produce IFN-γ \[[@pone.0233159.ref017], [@pone.0233159.ref018]\]. HTLV-1-infected T cells reportedly show autonomous proliferation and produce inflammatory cytokines such as IL-6, TNF-alpha and IFN-γ \[[@pone.0233159.ref018]\]. HTLV-1 infection alters the original function of T cells via HTLV-1-associated proteins such as Tax and HBZ \[[@pone.0233159.ref018]\]. In HTLV-1-positive RA patients, these IFN-γ producing cells, which are suspected to be HTLV-1-infected T cells, may be responsible for the invalid T-SPOT.*TB* assay results.

In the present study, spot count in the negative control panels tended to be higher among HTLV-1-positive RA patients with high HTLV-1 PVL. Elevated PVL indicates an increased number of HTLV-1-infected T cells in carriers. In addition, high PVL is a risk factor for the development of ATL and HAM/TSP \[[@pone.0233159.ref029], [@pone.0233159.ref030]\]. Compared with healthy HTLV-1-negative patients or asymptomatic HTLV-1 carriers, HAM/TSP patients are characterized by elevated plasma levels of proinflammatory cytokines, such as IL-4, IL-6, IL-8, IFN-γ, and TNF-α \[[@pone.0233159.ref018]\]. IFN-γ-producing Th1-like HTLV-1-infected T cells play a crucial role in the pathogenesis of HAM/TSP. Our results suggest that the number of IFN-γ-producing HTLV-1-infected T cells is increased in HTLV-1-positive RA patients with high HTLV-1 PVL. However, the contribution of IFN-γ-producing, HTLV-1-infected T cells to RA pathogenesis remains unclear. Our previous studies indicated that HTLV-1-positive RA patients exhibit higher levels of inflammation and a poorer response to anti-TNF agents than HTLV-1-negative RA patients \[[@pone.0233159.ref031], [@pone.0233159.ref032]\]. In the future, an *ex vivo* study is necessary to investigate the pathologic role of IFN-γ-producing HTLV-1-infected T cells in HTLV-1-positive RA patients.

The present study has several limitations. First, the sample size was small. In addition, the clinical imformation was retrospectively collected from medical records; further, some items, such as autoantibodies associated with RA, disease activity scores, and TST results, were not completely assessed in this study. Because the inclusion criteria of this study was set as RA patients who underwent T-SPOT.*TB* assay for LTBI screening, the number of HTLV-1-positive RA patients who were enrolled can be small. Second, this study enrolled HTLV-1-positive RA patients but not asymptomatic HTLV-1 carriers. It remains unclear whether HTLV-1 infection invalidates T-SPOT.*TB* assay in asymptomatic HTLV-1 carriers. Therefore, the invalid results of the T-SPOT.*TB* assay due to HTLV-1 infection may not be generalizable for the population of asymptomatic HTLV-1 carriers. To clarify the impact of HTLV-1 infection in the T-SPOT.*TB* assay results, future studies including a large number of HTLV-1-positive RA patients as well as asymptomatic HTLV-1 carriers are required. Third, this study only evaluated the effect of HTLV-1 infection on T-SPOT.*TB* assay results. QFT results were not studied because only few HTLV-1 RA Miyazaki Cohort Study participants had undergone QFT assay. In the future, we plan to conduct a large-scale study involving both HTLV-1-positive RA patients and asymptomatic HTLV-1 carriers to further investigate the validity of both the T-SPOT.*TB* and QFT assays in these patients. Finally, the present study did not directly identify the specific cell type that was producing IFN-γ. Future studies should analyze IFN-γ production by HTLV-1-infected T cells using flow cytometry or *in vitro* cytokine arrays. In addition, the gene expression of HTLV-1-associated proteins, such as Tax and HBZ, should be investigated in IFN-γ-producing cells isolated from HTLV-1-positive RA patients.

In conclusion, invalid T-SPOT.*TB* assay results were observed in approximately half of HTLV-1-positive RA patients but not in HTLV-1-negative RA patients. Therefore, T-SPOT.*TB* assay results should be interpreted with caution when screening for LTBI in HTLV-1-positive RA patients. It remains unclear whether IFN-γ-producing cells in HTLV-1-positive RA patients have an effect on the inflammatory response in RA. Future investigation of the role played by these IFN-γ-producing cells may elucidate the pathogenesis of HTLV-1-associated diseases, such as HAM/TSP, as well as the interaction of inflammatory diseases, such as RA, with HTLV-1.

Supporting information {#sec017}
======================

###### Characteristics of HTLV-1-positive rheumatoid arthritis patients with between negative and invalid results of T-SPOT.*TB* assay.

(DOCX)

###### 

Click here for additional data file.
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Dear Dr Umekita,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, both reviewers found some interests in this study, but pointed out a number of criticisms that require improvement or even amendment. I request the authors to respond fully to all comments made by reviewers. 

We would appreciate receiving your revised manuscript by May 04 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.
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Masataka Kuwana, MD, PhD

Academic Editor
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2\. Please note that PLOS does not permit references to "data not shown." Authors should provide the relevant data within the manuscript, the Supporting Information files, or in a public repository. If the data are not a core part of the research study being presented, we ask that authors remove any references to these data.

3\. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a description of how participants were recruited, and d) descriptions of where participants were recruited.

4\. Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation.

5\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

6\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this manuscript, the author presented HTLV-1 infection might affect T-SPOT.TB assay results in RA patients. They showed that T-SPOT. TB assay may not be a reliable LTBI screening tool in approximately half of the HTLV-1-positive patients. The author explained that the cause of invalid results in HTLV-1-positive patients was a high spot count in the negative controls of the assay. This phenomenon indicates the presence of autonomous IFN-γ producing cells without specific TB-antigen stimulation. The subject matter is impressive; however, much improvement can still be made to make it more unambiguous and more concise. The following are the points I raise after reading this manuscript.

Major points

1\. In this study, 75 of 165 HTLV-1-negative and 29 of 55 HTLV-1-positive RA patients from 861 RA patients in the HTLV-1 RA cohort were enrolled. Please show the patient registration process flowchart for this study in the figure.

2\. Paragraph on study design and participants, page 5, please specify the \"initial study criteria,\" and in particular, the eligibility criteria and the sources and methods of selection of participants, according to the STROBE checklist.

3\. T-Spot TB tests may also be positive in patients with a previous history of TB. What was the proportion of patients with a history of TB in the HTLV -1 positive and negative groups?

4\. Even if the result of the T-spot TB test is invalid, it is necessary to evaluate some TB infection before the treatment of csDMARDs or biologic DMARDs. How did the author assess the 16 patients with an invalid T-spot TB test in the 29 HTLV -1 positive group for M. tuberculosis infection?

5\. In the discussion section, please describe your efforts to address potential sources of bias, as per the STROBE checklist, addressing in particular confounding variables, lack of generalizability, selective reporting, post hoc analyses, and data dredging. In the paragraph on limitations (page 14-15)

Minor points

1\. Anti-rheumatic treatment is misspelled on page 5 of line 16.

2\. Please add a 95% confidence interval for the odds ratio of patients with HTLV-1 positive RA who have an invalid T-spot TB test result to patients with negative RA (Table 2).

Reviewer \#2: Dear the author,

This article describes the tendency of invalid result in T-SPOT.TB assay among RA patients.

It seems important as well as interesting because using bDMARDs increases the possibility of symptomatic TB infection, and according to the manuscript physicians must pay attention how to interpret T-SPOT.TB assay from HTLV-1 positive RA patients.

However, there are a few minor issues that should be modified by the authors.

1\. If the number of HTLV-1 positive patients to whom LTBI screening were carried out were twenty-nine, age- and sex- matching of HTLV-1 negative RA patients should be done with such 29 patients, not with 55 patients, even if the result as shown in Table 1 was suitable for continuing the study.

2\. In page 5, line 16, "anti-fheumatic" should be replaced with "anti-rheumatic".

3\. To evaluate the appropriate comparison, WBC count and/or Lymphocyte count should be added in Table 1.

4\. According to the result of T-SPOT.TB assay in HTLV-1 positive patients, spot count in the negative controls tends to \>10 but that in EAST-6 and CFP10 are almost zero. Authors should explain the discrepancy. could the proteins eliminate the production of IFN-gamma from T cells in HTLV-1 positive patients?

5\. How about a tuberculin reaction in HTLV-1 positive patients? Previous report should be cited in discussion page.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Kosaku Murakami

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0233159.r002

Author response to Decision Letter 0

27 Apr 2020

Respond to Reviewer's comments.

Dear Editor and Reviewers,

Thank you for your careful review and the pertinent and insightful comments.

We have revised our manuscript following reviewer's suggestions. We hope that our edits and the responses we provide below satisfactorily address all the issues and concerns you and the reviewers have noted.

Best regards,

Kunihiko Umekita

Reviewer \#1: In this manuscript, the author presented HTLV-1 infection might affect T-SPOT.TB assay results in RA patients. They showed that T-SPOT. TB assay may not be a reliable LTBI screening tool in approximately half of the HTLV-1-positive patients. The author explained that the cause of invalid results in HTLV-1-positive patients was a high spot count in the negative controls of the assay. This phenomenon indicates the presence of autonomous IFN-γ producing cells without specific TB-antigen stimulation. The subject matter is impressive; however, much improvement can still be made to make it more unambiguous and more concise. The following are the points I raise after reading this manuscript.

Major points

1\. In this study, 75 of 165 HTLV-1-negative and 29 of 55 HTLV-1-positive RA patients from 861 RA patients in the HTLV-1 RA cohort were enrolled. Please show the patient registration process flowchart for this study in the figure.

We thank you for your suggestion. In line with a comment from another reviewer, we changed the study design to a case control study. In addition, we invited a specialist for medical statistics in the present study. We revised the method of statistical analysis because of change the study design (Page 9, line 151 to line 159). We selected three age- and sex-matched patients with HTLV-1-negative RA for each patient with HTLV-1-positive RA as controls. Eighty-seven patients with HTLV-1-negative RA and 29 patients with HTLV-1-positive RA were enrolled in this study (Page 5, line 91 to Page 6, line 106). We presented the patient registration process flowchart in Figure 1.

2\. Paragraph on study design and participants, page 5, please specify the \"initial study criteria,\" and in particular, the eligibility criteria and the sources and methods of selection of participants, according to the STROBE checklist.

We described the initial study criteria, the eligibility criteria, and the sources and methods of patient selection according to the STROBE checklist (Page 5, line 91 to page 6, line 106).

3\. T-Spot TB tests may also be positive in patients with a previous history of TB. What was the proportion of patients with a history of TB in the HTLV -1 positive and negative groups?

We appreciate your comment. We collected data on the history of TB infection from the patients' medical records. No patients with HTLV-1-positive RA had a history of TB, compared with one patient with HTLV-1-negative RA. The positive result was obtained using the T-SPOT.TB assay. We have added this information in the Results (Page 10, Lines 171--174).

4\. Even if the result of the T-spot TB test is invalid, it is necessary to evaluate some TB infection before the treatment of csDMARDs or biologic DMARDs. How did the author assess the 16 patients with an invalid T-spot TB test in the 29 HTLV -1 positive group for M. tuberculosis infection?

We thank you for your comment. In daily practice, we evaluate latent TB infection (LTBI) using IGRAs such as T-SPOT.TB and radiologic examinations such as high-resolution computed tomography (HRCT) of the chest. Additionally, it is important to assess the history of TB infection. Of the 16 patients with an invalid T-SPOT.TB assay result, two participants with suspicious findings of LTBI on chest HRCT were administrated prophylactic regimens targeting TB reactivation such as isoniazid before starting anti-rheumatic biologic therapy. In the present study, based on the history of TB infection, T-SPOT.TB result, and HRCT findings, 19 patients with HTLV-1-negative RA and 3 patients with HTLV-1-positive RA were treated with isoniazid as prophylaxis. We described this information in the Discussion (Page 16, Line 207 to Page 17, Line 225).

5\. In the discussion section, please describe your efforts to address potential sources of bias, as per the STROBE checklist, addressing in particular confounding variables, lack of generalizability, selective reporting, post hoc analyses, and data dredging. In the paragraph on limitations (page 14-15)

We described the limitation according to the STROBE checklist (Page 19, Line 261 to Page 20, Line 271)

Minor points

1\. Anti-rheumatic treatment is misspelled on page 5 of line 16.

We corrected the spelling of this word．

2\. Please add a 95% confidence interval for the odds ratio of patients with HTLV-1 positive RA who have an invalid T-spot TB test result to patients with negative RA (Table 2).

We provided the 95% confidence interval in Table 2.

Reviewer \#2: Dear the author,

This article describes the tendency of invalid result in T-SPOT.TB assay among RA patients.

It seems important as well as interesting because using bDMARDs increases the possibility of symptomatic TB infection, and according to the manuscript physicians must pay attention how to interpret T-SPOT.TB assay from HTLV-1 positive RA patients.

However, there are a few minor issues that should be modified by the authors.

1\. If the number of HTLV-1 positive patients to whom LTBI screening were carried out were twenty-nine, age- and sex- matching of HTLV-1 negative RA patients should be done with such 29 patients, not with 55 patients, even if the result as shown in Table 1 was suitable for continuing the study.

We thank you for your suggestion. We changed the study design to a case control study according to your suggestion. Therefore, we invited a specialist for medical statistics because of change the study design. We described the protocol in the methods section (Page 5, Line 91 to Page 6, Line 106). In addition, we revised the method of statistical analysis (Page 9, line 151 to line 159). We presented the flowchart of patient selection as Figure 1 according to the suggestion of another reviewer.

2\. In page 5, line 16, "anti-fheumatic" should be replaced with "anti-rheumatic".

We corrected the spelling of this word.

3\. To evaluate the appropriate comparison, WBC count and/or Lymphocyte count should be added in Table 1.

We added data for the WBC and lymphocyte counts in Table 1.

4\. According to the result of T-SPOT.TB assay in HTLV-1 positive patients, spot count in the negative controls tends to \>10 but that in EAST-6 and CFP10 are almost zero. Authors should explain the discrepancy. could the proteins eliminate the production of IFN-gamma from T cells in HTLV-1 positive patients?

We thank you for your comments. In this assay, when high background staining hinders the discrimination of the spots from the background, the results should be considered invalid. Therefore, if the negative control spot count exceeds 10, the T-SPOT.TB result should be considered invalid regardless of the spot counts in both panels A and B. Several clinical laboratory companies report spot counts as zero in both panels A and B in the T-SPOT-TB assay if they observe high negative control spot counts. In the present study, we initially used a count of zero to indicate unevaluable results in Table 3 in line with the reports of clinical laboratory companies. To avoid reader confusion, we would like to use asterisks (\*) to indicate unevaluable results for both panels A and B in Table 3. We described the assessment of the T-SPOT.TB assay in detail in the methods section (Page 7, lines 122 - 127). In addition, we described the meaning of this symbol in Table 3.

5\. How about a tuberculin reaction in HTLV-1 positive patients? Previous report should be cited in discussion page.

In the present study, 46 patients with HTLV-1-negative RA and 13 patients with HTLV-1-positive RA underwent tuberculin skin tests (TSTs) during the observation period. The proportion of patients with negative TST results tended to be higher in the HTLV-1-positive RA group than in the HTLV-1-negative RA group (77% versus 67%, P = 0.73). We described this finding in the Results (Page 10, Line 174 to line 177).

Some previous reports suggested that HTLV-1 infection can attenuate the response to purified protein derivative (PPD) of Mycobacterium tuberculosis. The proportion of HTLV-1 carriers who had a low response to PPD was reported to range 65--70% (Ref. 15--16).

The proportion of patients with negative TST results in the present study tended to be higher than those of previous studies. It is well known that the reaction to PPD diminishes with age. One reason for this tendency observed in the present study could be the higher median age of the participants compared with previous reports (70 years versus 63 years).

Several studies suggested that immunosuppressive treatments can affect the response to PPD. In patients with rheumatic diseases who have been treated with immunosuppressive agents, TST is hampered by low positive and negative predictive values (Ref. 31--32). The background therapeutic regimen was nearly identical between the HTLV-1-negative and HTLV-1-positive RA groups in the present study. Therefore, it was considered that HTLV-1 infection can attenuate the TST result in patients with HTLV-1-positive RA.

We describe these findings in the Discussion (Page 17, Line 226 to Page 18, Line 238).

###### 
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Dear Dr. Umekita,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Masataka Kuwana, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have satisfactorily responded to all my questions and made the necessary changes to the manuscript. So, I have no further comments in this manuscript.

Reviewer \#2: Dear the author, The manuscript \"Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: a retrospective case-control observational study\" (PONE-D-20-06768R1) was properly edited according to the reviewers\' comments.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Kosaku Murakami
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Human T-cell leukemia virus type 1 may invalidate T-SPOT.*TB* assay results in rheumatoid arthritis patients: a retrospective case-control observational study

Dear Dr. Umekita:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Masataka Kuwana

Academic Editor

PLOS ONE
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